OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) presented preclinical efficacy data for novel agonist monoclonal antibody therapy, OSE-230, at the 2020... View Article
New member | KetoM+ Medical Food
KetoM+: Facilitate the access for therapeutic metabolic diets KetoM+ develops a new generation of ketogenic products adapted to therapeutic diets.... View Article
Biofortis and ProDigest announce an agreement for a global collaboration in the field of gastrointestinal research
ProDigest, specialists in intestinal research and Biofortis, Mérieux NutriSciences’ Contract Research Organization serving innovation in nutrition, health, and microbiota studies,... View Article
Owkin and Nantes University Hospital (CHU Nantes) to Advance Cancer Research with Artificial Intelligence
Owkin, a startup that deploys AI and Federated Learning technologies to augment medical research and enable scientific discoveries, announces a... View Article
Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19
Eurofins U.S. Clinical Diagnostics, announced that Clinical Enterprise Inc. has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration... View Article
CE4BIG: Launch of the ClusterXchange Scheme!
The project CE4BIG – Cluster Excellence for Business Innovation and Growth in the Health Sector – funded under the EU... View Article
Valneva’s Chikungunya Vaccine Candidate Awarded EMA Prime Designation
Valneva SE a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced that the European... View Article
ProfileHIT develops a STOP-COVID19 research program’s
As part of the R&D effort provided since March 2020 by biotech companies located in Nantes in order to fight... View Article
New member | Satisform
Satisform is a French company based in Le Mans. It designs and produces medical devices used in rehabilitation and preventive... View Article
OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104
The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases,... View Article